ECUR 506
Alternative Names: ECUR-506; GTP-506Latest Information Update: 10 May 2024
At a glance
- Originator iECURE
- Class Gene therapies
- Mechanism of Action Gene transference; Ornithine carbamoyltransferase replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Ornithine carbamoyltransferase deficiency disease
Most Recent Events
- 08 May 2024 ECUR 506 receives Fast Track designation for Ornithine carbamoyltransferase deficiency disease [IV,Infusion] in USA
- 30 Apr 2024 Phase-I/II clinical trials in Ornithine carbamoyltransferase deficiency disease (In infants, In neonates) in United Kingdom (IV) (NCT06255782)
- 04 Apr 2024 iECURE plans a phase I/II OTC-HOPE trial in Ornithine carbamoyltransferase deficiency disease (In infants; In neonates) in Australia, US and the United Kingdom (IV, Infusion) in 2024 (NCT06255782)